Eliana Clark

CIK: 0001914448

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (75.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NTLA

Intellia Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

NTLA
Intellia Therapeutics, Inc.
Mar 2, 2026
Sale(S)
Direct
607 shares at avg. $13.78$8K
NTLA
Intellia Therapeutics, Inc.
Mar 1, 2026
Award(A)
Direct
7.4K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
9.5K shares at avg. $9.21$88K
NTLA
Intellia Therapeutics, Inc.
Jul 1, 2025
Sale(S)
Direct
1K shares at avg. $9.82$10K
NTLA
Intellia Therapeutics, Inc.
Mar 4, 2025
Sale(S)
Direct
679 shares at avg. $8.99$6K
NTLA
Intellia Therapeutics, Inc.
Mar 1, 2025
Award(A)
Direct
32K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 3, 2025
Sale(S)
Direct
7.4K shares at avg. $12.18$90K
NTLA
Intellia Therapeutics, Inc.
Jan 2, 2025
Sale(S)
Direct
556 shares at avg. $12.03$7K

		Type	Shares	Price		Ownership
Mar 2, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	607	$13.78	$8,364	Direct
Mar 1, 2026	NTLA Intellia Therapeutics, Inc.	Award(A)	7,353	-	$0	Direct
Jan 5, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	9,515	$9.21	$87,633	Direct
Jul 1, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	1,022	$9.82	$10,036	Direct
Mar 4, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	679	$8.99	$6,104	Direct
Mar 1, 2025	NTLA Intellia Therapeutics, Inc.	Award(A)	32,000	-	-	Direct
Jan 3, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	7,422	$12.18	$90,400	Direct
Jan 2, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	556	$12.03	$6,689	Direct

1-8 of 8 transactions

About Clark Eliana

Clark Eliana (SEC CIK 0001914448) files insider reports with the SEC as EVP, Chief Technical Officer of Intellia Therapeutics, Inc. (NTLA).

Signal8 holds 5 ownership filings by Clark Eliana, all Form 4s, filed between Jan 6, 2025 and Mar 3, 2026. Those filings report 8 transactions, from Jan 2, 2025 to Mar 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Clark Eliana's filings is in CAMBRIDGE, MA.

Recent filings by Clark Eliana

Mar 2, 2026: Open-market sale of NTLA shares (Form 4, code S).
Mar 1, 2026: Grant or award of NTLA shares (Form 4, code A).
Jan 5, 2026: Open-market sale of NTLA shares (Form 4, code S).
Jul 1, 2025: Open-market sale of NTLA shares (Form 4, code S).
Mar 4, 2025: Open-market sale of NTLA shares (Form 4, code S).

Other insiders filing for Intellia Therapeutics, Inc. (NTLA)

Marantz Jing L., EVP, Chief Medical Officer
Dube Michael P, VP, Chief Accounting Officer
LEONARD JOHN M, President and CEO
Dulac Edward J III, EVP, Chief Financial Officer
Verwiel Frank, Director
Keresty Georgia, Director

How to read Form 4 transaction codes